Numerous neurodegenerative diseases are characterized by the accumulation of tau aggregates. Targeting tau oligomers can lead to the development of effective treatments for these diseases.

Alzheimer’s disease Hallervorden-Spatz disease
Amyotrophic lateral sclerosis/parkinsonism-dementia complexa Myotonic dystrophy
Argyrophilic grain dementiaa Niemann-Pick disease, type C
Chronic Traumatic Encephalopathya (traumatic brain injury) Non-Guamanian motor neuron disease with neurofibrillary tangles
Creutzfeldt-Jakob disease Pick’s diseasea
Corticobasal degenerationa Postencephalitic parkinsonism
Diffuse neurofibrillary tangles with calcificationa Prion protein cerebral amyloid angiopathy
Down’s syndrome Progressive subcortical gliosisa
Frontotemporal dementia with parkinsonism linked to chromosome 17a Progressive supranuclear palsya
Gerstmann-Sträussler-Scheinker disease Subacute sclerosing panencephalitis

aDiseases in which tau-positive neurofibrillary pathology is the most predominant neuropathologic feature. Lee et al., Annu. Rev. Neurosci. 2001, 24:1121.